# OnCo record idh-mutant-astrocytoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/idh-mutant-astrocytoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "idh-mutant-astrocytoma" ;
  schema:name "Astrocytoma, IDH-mutant (grades 2 to 4)"@en ;
  schema:alternateName "IDH-mutant astrocytoma"@en, "Diffuse astrocytoma, IDH-mutant"@en, "Anaplastic astrocytoma, IDH-mutant"@en, "Lower-grade glioma"@en, "Low-grade glioma (adult)"@en ;
  schema:description "IDH-mutant astrocytoma is the slow-growing form of adult glioma, defined by a mutation in the IDH1 or IDH2 gene that makes the tumour produce a chemical which rewires its own cells. Surgery first, and then either watchful waiting, the new pill vorasidenib, or radiotherapy with chemotherapy, depending on grade and how much tumour is left."@en ;
  schema:url <https://onco.cc/cancers/idh-mutant-astrocytoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Astrocytoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Astrocytoma>, <https://doi.org/10.1056/NEJMoa2304194>, <https://doi.org/10.1056/NEJMoa1500925> ;
  onco:tag "subtype-page", "cns" ;
  onco:related <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/oligodendroglioma/>, <https://onco.cc/cancers/brain-tumours/> ;
  onco:technologies <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/extent-of-resection/> ;
  onco:targets <https://onco.cc/targets/idh/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/vorasidenib/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/vincristine/> ;
  onco:companies <https://onco.cc/companies/servier/> ;
  onco:pathways <https://onco.cc/pathways/glioma-signalling/> ;
  onco:terms <https://onco.cc/terms/mgmt/>, <https://onco.cc/terms/re-irradiation/>, <https://onco.cc/terms/blood-brain-barrier/> ;
  onco:trials <https://onco.cc/trials/indigo/>, <https://onco.cc/trials/catnon/>, <https://onco.cc/trials/eortc-22033/>, <https://onco.cc/trials/nct05303519/> ;
  onco:pipeline <https://onco.cc/drugs/vorasidenib/>, <https://onco.cc/drugs/safusidenib/>, <https://onco.cc/drugs/olutasidenib/>, <https://onco.cc/technologies/methylation-profiling/> ;
  onco:standardOfCare <https://onco.cc/terms/extent-of-resection/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/drugs/vorasidenib/>, <https://onco.cc/trials/indigo/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/trials/eortc-22033/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/trials/catnon/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/trials/eortc-26981/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/bevacizumab-glioma/>, <https://onco.cc/terms/re-irradiation/> .